Among the 52 trastuzumab untreated patients, RT-qPCR classified the tumors of 21 as HER2 positive with 5 events (4 recurrences and 1 death) and the tumor of the remaining 31 as HER2 negative with 11 events (6 recurrences and 5 deaths). This evidence concerns the gene ERBB2 and neoplasm.